Furthermore, there are data to suggest that targeted agents may change the tumor immune environment and potentially synergize with immunotherapy.8,9 We hypothesized that combining a PD-L1 inhibitor (atezolizumab) with targeted therapy would lead to improved OS in patients with ATC. This evidence concerns the gene CD274 and neoplasm.